Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.
Bashir B, Wang JS, Falchook G, Fontana E, Arkenau HT, Carter L, Galot R, Basu B, Greystoke A, Subbiah V, Richardson DL, Orr H, Bennett G, Sharma R, Xu H, Paganoni P, Xu C, Campbell C, McKean M.
Bashir B, et al. Among authors: bennett g.
J Clin Oncol. 2024 Oct 10;42(29):3443-3452. doi: 10.1200/JCO.23.01107. Epub 2024 Sep 4.
J Clin Oncol. 2024.
PMID: 39231383
Clinical Trial.